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• Erythrocytosis (high hemoglobin) most common-
ly results from secondary causes such as hypox-
ia (Box 1), but it may also be caused by a prima-
ry, underlying condition known as polycythemia 
vera (PV). 
• PV is a rare cancer of the bone marrow which 
causes an increased production of red blood 
cells and may lead to complications such as clot-
ting, itchiness from water, an enlarged spleen, 
and possible transformation into acute leukemia. 
• To distinguish PV from secondary erythrocyto-
sis, a molecular test can be performed which se-
quences the Janus kinase 2 (JAK2) gene and 
looks for a mutation which is present in 95% of 
PV patients. 
• At LHSC, an increase in molecular testing for pa-
tients with suspected PV and a decrease in the 
number of positive tests suggests that this test 
is being overused. 
• The objective of our study was to develop a sim-
ple rule to help physicians distinguish between 
PV and other secondary causes of erythrocyto-
sis in order to reduce indiscriminate ordering of 
JAK2 mutation testing. 
BACKGROUND  
Data Collection 
• Between January 2018 and May 2021, patients 
with hemoglobin levels ≥ 160 g/L (women) or 
165 g/L (men) who underwent JAK2 mutation 
testing at LHSC using the next-generation se-
quencing (NGS)-based Oncomine Myeloid Re-
search Assay (ThermoFisher Scientific, MA, 
USA) were identified. 
• Age, sex, and complete blood count parameters 
were extracted from their electronic records. 
• Patients were divided into two cohorts by year: 
o Derivation cohort (2018–2019) 
o Validation cohort (2020–2021) 
Derivation of the Prediction Rule 
• In the derivation cohort, potentially significant 
predictors of JAK2 positivity were identified, di-
chotomized using receiver operating character-
istic curves, and modelled using multivariable 
stepwise logistic regression analysis. 
• The final model was evaluated using the Hosmer
-Lemeshow test and pseudo-R2 measures, and 
internally validated using logistic regression and 
non-parametric bootstrapping. 
 
Validation of the Prediction Rule 
• The rule was applied to both cohorts to validate 
and assess the rule’s performance. 
• Sensitivity: the percentage of patients with a 
JAK2 mutation who are correctly identified by 
the rule. 
• Specificity: the percentage of patients without a 
JAK2 mutation who are correctly identified by 
the rule. 
• Positive predictive value (PPV): the probability 
that the prediction rule correctly identifies the 
presence of a JAK2 mutation. 
• Negative predictive value (NPV): the probability 
that the prediction rule correctly identifies the 
absence of a JAK2 mutation. 
Do not test for JAK2 mutations Test for JAK2 mutations 
Figure 1. Flowchart illustrating the prediction rule that was generated to 
help guide JAK2 mutation testing. The rule uses the red blood cell and 
platelet counts, both of which are routinely and easily measured as part 
of a complete blood count. 
Red blood cell count > 6.17 × 1012/L 
or 
Platelet count > 308 × 109/L 





(n = 308) 
Validation cohort 
(n = 223) 
Age, mean (SD) 58 (14) 59 (14) 
Male sex, number (%) 229 (74) 161 (73) 
Leukocytes, mean (SD) (× 109/L) 9.1 (4.1) 9.1 (3.3) 
Erythrocytes, mean (SD) (× 1012/L) 5.87 (0.66) 5.91 (0.57) 
Hemoglobin, mean (SD) (g/L) 177 (12) 177 (11) 
Hematocrit, mean (SD) (L/L) 0.53 (0.04) 0.53 (0.04) 
Platelets, mean (SD) (× 109/L) 269 (162) 278 (168) 
Neutrophils, mean (SD) (× 109/L) 5.9 (4.3) 5.9 (2.4) 
• In the derivation cohort, the prediction rule accurately identified 86.8% of JAK2-positive patients while 
correctly screening out 97.4% of patients as being JAK2-negative (Table 2). Similarly, in the validation co-
hort, the prediction rule accurately identified 100% of JAK2-positive patients while correctly screening out 
100% of patients as being JAK2-negative (Table 2). 
• Over 300 tests between January 2018 and May 2021 could have been avoided by using this prediction 
rule, a reduction of approximately 60% (Table 3). 
• In summary, we developed and validated a simple rule to predict the likelihood of a JAK2 mutation in pa-
tients with elevated hemoglobin levels which could improve resource allocation and reduce unnecessary 
testing. 
Table 3. Contingency table for the JAK2 pre-
diction rule. Bolded numbers in purple indi-
cate the number of tests which could have 





































Sensitivity 86.8% 100% 
Specificity 68.9% 62.1% 
PPV 28.2% 20.6% 
NPV 97.4% 100% 
Table 2. JAK2 prediction rule performance 
for each of the cohorts. PPV, positive predic-
tive value; NPV, negative predictive value.  
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METHODS  
Table 1. Characteristics of the derivation and validation cohorts. 
CONCLUSION  
Box 1. Common causes of erythrocytosis. 
• Primary 
o Polycythemia vera (PV) 
• Secondary 
o Hypoxia (e.g. smoking, chronic obstructive pul-
monary disorder, obstructive sleep apnea) 
o Medications (e.g. testosterone, sodium/glucose 
cotransporter 2 [SGLT2] inhibitors) 
o Erythropoietin-secreting tumours (e.g. renal cell 
carcinoma, hepatocellular carcinoma) 
